(Q36567094)

15 August 2017

1 reference

title

Anti-angiogenic therapy: Prospects for treatment of ocular tumors (English)

1 reference

15 August 2017

main subject

angiogenesis inhibitor

1 reference

Mark I Rosenblatt

1

1 reference

15 August 2017

Dimitri T Azar

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Seminars in Ophthalmology

15 August 2017

published in

1 reference

15 August 2017

volume

21

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

151-160

1 reference

Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Matrix metalloproteinases and matrikines in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Antiangiogenic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Mechanisms of angiogenesis and arteriogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Manipulating angiogenesis in medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

VEGF: an update on biological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

A reevaluation of integrins as regulators of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

VEGF receptor signaling and endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Antiangiogenic therapy for von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

The impact of anti-angiogenic agents on cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Promises and pitfalls of anti-angiogenic therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Higher vessel densities in retinoblastoma with local invasive growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Cancer anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

von Hippel-Lindau disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Anti-angiogenic therapy for uveal melanoma--more haste, less speed

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Resistance in the anti-angiogenic era: nay-saying or a word of caution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08820530500350787

10.1080/08820530500350787

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference